Important note: This article is intended for those who understand vaccines as critical to maintaining their health and that of their families. It is NOT intended for those who are anti-vaccine and as such is NOT intended to foster a discussion on the merits of vaccines in this forum. It is also NOT intended to foster a discussion of the lethality of COVID-19 or the need for civic action to limit the spread of the disease.
- Among individuals who had an allergic reaction to their first mRNA COVID-19 vaccine dose, all who went on to receive a second dose tolerated it.
- Even some who experienced anaphylaxis following the first dose tolerated the second dose.
In a multi-hospital analysis of individuals who experienced an allergic reaction to their first mRNA COVID-19 vaccine dose, all patients who went on to receive a second dose tolerated it without complications. The research, which was led by allergists at Massachusetts General Hospital (MGH) and is published in JAMA Internal Medicine, indicates that a first dose reaction to COVID-19 vaccination should not keep people from getting a second dose.
Allergic reactions after mRNA COVID-19 vaccinations have been reported to be as high as 2%, with anaphylaxis—a life-threatening whole-body allergic reaction—occurring in up to 2.5 per 10,000 people. To examine whether it’s safe to proceed with a second mRNA COVID-19 vaccine dose after a dose one reaction, investigators from MGH, Vanderbilt University Medical Center, University of Texas Southwestern Medical Center and Yale School of Medicine combined data from patients who sought allergy specialist care at their hospitals after a reaction to their first mRNA COVID-19 vaccine dose. “These reactions could include symptoms such as itching or hives or flushing. The patients included were all advised by allergy specialists after their dose one reaction,” explains co–lead author Matthew S. Krantz, MD, of Vanderbilt University Medical Center.
Among 189 patients, 32 (17%) experienced anaphylaxis after their first dose of mRNA COVID-19 vaccine. A total of 159 patients (84%) went on to receive a second dose. All 159 patients, including 19 individuals who had experienced anaphylaxis following the first dose, tolerated the second dose. Thirty-two patients (20%) reported immediate and potentially allergic symptoms associated with the second dose that were self-limited, mild, and/or resolved with antihistamines alone.
“One important point from this study is that these immediate onset mRNA vaccine reactions may not be mechanistically caused by classic allergy, called immediate hypersensitivity or Ig-E–mediated hypersensitivity. For classic allergy, re-exposure to the allergen causes the same or even worse symptoms,” says co–senior author Kimberly G. Blumenthal, MD, MSc, co-director of the Clinical Epidemiology Program within MGH’s Division of Rheumatology, Allergy and Immunology.
The study’s findings suggest that it’s safe for most individuals to receive a second dose of the mRNA COVID-19 vaccine, notes co–senior author Aleena Banerji, MD, clinical director of the Allergy and Clinical Immunology Unit at MGH. “After first dose reactions, allergy specialists may be useful to help guide risk/benefit assessments and assist with completion of safe vaccination,” she says.
This study was funded by the National Institutes of Health and MGH.
The article is published in JAMA Internal Medicine.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of “America’s Best Hospitals.”